Genscript Biotech's high P/S ratio is due to its promising revenue outlook. The company's strong performance and bright future are likely to keep supporting the share price unless conditions change.

GenScript's leadership values Dr. Liu's expertise in genome editing, chemistry, and synthetic biology for its potential to offer key insights. His addition to the SAB is anticipated to boost GenScript's platform and hasten transformative breakthroughs for patients.

Dr. June joining GenScript's SAB could provide invaluable insights for their initiatives, especially in cell and gene therapy. His expertise may accelerate the development of novel therapies.

Despite Genscript Biotech's promising revenue outlook, its P/S ratio isn't higher than industry peers due to potential volatility in revenue forecasts. Investors should note the company's 2 warning signs.

The continuous sell-off of shares by insiders could be concerning for shareholders, as this does not reflect confidence in the company’s outlook. This activity indicates that investors may need to exercise caution when considering investment in Genscript Biotech.

Genscript Biotech, though in debt, retains substantial net cash, suggesting manageable debt. Its remarkable revenue surge last year could point to future profitability, but its presently unprofitability at the EBIT level and recent negative cash outflows suggest more capital might be needed. The overall risk for Genscript Biotech is notable at this point.